The demographic characteristics and baseline laboratory values for the trial population. The sample included 402 (98%) Caucasians, 1 black, 3 Orientals, and 6 patients of other ethnic origin. Of the trial population, 23% (n = 95) of patients received dopamine agonists, 87% reported drinking caffeine (n = 358), 57% (n = 234) reported drinking alcohol and 10% (n = 42) were smokers. All data are given as median values (minimum—maximum value).